Charles Schwab
AUPH icon

Charles Schwab’s Aurinia Pharmaceuticals AUPH Stock Holding History

Charles Schwab’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$7.57M Sell
445,990
-15,876
-3% -$254K ﹤0.01% 2288
2026
Q1 		$6.84M Buy
461,866
+29,398
+7% +$430K ﹤0.01% 2268
2025
Q4 		$6.9M Sell
432,468
-5,479
-1% -$77.7K ﹤0.01% 2309
2025
Q3 		$4.84M Sell
437,947
-73,784
-14% -$806K ﹤0.01% 2453
2025
Q2 		$4.33M Sell
511,731
-9,685
-2% -$77.6K ﹤0.01% 2386
2025
Q1 		$4.19M Sell
521,416
-143,671
-22% -$1.16M ﹤0.01% 2339
2024
Q4 		$5.97M Sell
665,087
-78,963
-11% -$644K ﹤0.01% 2255
2024
Q3 		$5.45M Buy
744,050
+89,940
+14% +$558K ﹤0.01% 2328
2024
Q2 		$3.73M Buy
654,110
+115,152
+21% +$606K ﹤0.01% 2484
2024
Q1 		$2.7M Buy
538,958
+100,767
+23% +$684K ﹤0.01% 2510
2023
Q4 		$3.94M Buy
438,191
+52,891
+14% +$436K ﹤0.01% 2407
2023
Q3 		$2.99M Buy
385,300
+73,746
+24% +$721K ﹤0.01% 2463
2023
Q2 		$3.02M Buy
311,554
+5,570
+2% +$57.8K ﹤0.01% 2423
2023
Q1 		$3.35M Buy
305,984
+5,269
+2% +$46.4K ﹤0.01% 2371
2022
Q4 		$1.3M Buy
300,715
+4,414
+1% +$25.6K ﹤0.01% 2697
2022
Q3 		$2.23M Buy
296,301
+100
+0% +$866 ﹤0.01% 2555
2022
Q2 		$2.98M Buy
+296,201
New +$3.31M ﹤0.01% 2417

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $225B AUM 49.49% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's AUPH Position: Q2 2026 in Review

Charles Schwab reduced its Aurinia Pharmaceuticals (AUPH) stake by 3.4% in Q2 2026, selling an estimated $254K and leaving 445,990 shares worth $7.57M. The position accounts for ﹤0.01% of the portfolio, ranked #2288.

Charles Schwab first reported a position in AUPH in Q2 2022 and has held it in 17 quarters since. 281 funds tracked by Wall St. Rank hold AUPH as of Q2 2026.

  • Charles Schwab held 445,990 shares of Aurinia Pharmaceuticals worth $7.57M as of Q2 2026.
  • Charles Schwab sold 15,876 Aurinia Pharmaceuticals shares in Q2 2026, an estimated $254K.
  • Aurinia Pharmaceuticals made up ﹤0.01% of Charles Schwab's portfolio in Q2 2026, its #2288 holding.
  • Charles Schwab first reported a position in Aurinia Pharmaceuticals in Q2 2022 and has held it in 17 quarters since.
  • 281 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.